Stay updated with breaking news from Poster Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug) and emerging Globo H science. TAIPEI, Taiwan, April 7, 2022 /PRNewswire/ -- OBI Pharma
/PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab...
New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years the longest follow-up of any Bruton's tyrosine kinase inhibitor in multiple
Press release content from PR Newswire. The AP news staff was not involved in its creation.
The newsletter features stories from the Junior Investigators, the Pilot Project Awardees, the Research Cores, and COBRE collaborators.